Evidence map›Paper›PMID 34001685›Full record

ArticleThe Kobe journal of medical sciences2021

Can Japan Achieve Zero Transmission of HIV? Time Series Analysis Using Bayesian Local Linear Trend Model.

Kentaro Iwata, Chisato Miyakoshi

Abstract read
In one paragraph

Article in The Kobe journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kentaro IwataDivision of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-2, Chuoku, Kobe, Hyogo 650-0017, Japan.
Chisato MiyakoshiDepartment of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Minatojimaminamimachi 2-1-1, Kobe, Hyogo 650-0047 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of newly diagnosed human immunodeficiency virus (HIV) infections and acquired immune deficiency syndrome (AIDS) patients in Japan appears to be decreasing. However, whether these new infections cease to occur in the future in Japan, similar to abroad, is unclear. To evaluate the feasibility of this achievement, we conducted a time series analysis using Bayesian local linear trend model to evaluate the possibility of zero new infection of HIV/AIDS in Japan.

methodsWe used quarterly data on HIV/AIDS from the first quarter, 2001 to the second quarter, 2020. Bayesian analyses were conducted using Markov chain Monte Carlo (MCMC) method, and a local linear trend model was constructed for number of newly diagnosed HIV infection without AIDS diagnosis, AIDS cases, and their aggregate. Predictions for the following 60 quarters until the second quarter of 2035 were also made for all models.

resultsThe mean aggregate cases of HIV/AIDS patients became 0 by the fourth quarter of 2031 (90% credible interval 0-535). For HIV infections alone, mean cases became 0 by the second quarter of 2030 (90%CrI 0-472). For AIDS alone mean cases were 9 at the second quarter of 2035 (90%CrI 0-231).

conclusionOur local linear trend model suggested that number of HIV/AIDS cases in Japan could decrease to zero by the first quarter of 2031, if the trend of the infections followed the local linear trend model, yet with rather wide credible interval. Achieving zero new transmission of HIV in Japan is a realistic goal but measures to make it faster may be needed.

Indexed as

Bayes TheoremDisease Transmission, InfectiousHIV InfectionsHumansJapanPredictive Value of TestsforecastingHIVJapantime series analysis

Identifiers

PMID34001685
PMCPMC8212801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.